Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors
Aim. Sacubitril-valsartan has proven beneficial in heart failure with reduced ejection fraction. Guidelines recommend initiating half-dose sacubitril-valsartan before up-titration even to patients already on target dose angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers...
Saved in:
Main Authors: | Helena Norberg, Ellinor Bergdahl, Krister Lindmark |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Cardiovascular Therapeutics |
Online Access: | http://dx.doi.org/10.1155/2019/6745074 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of creatinine‐based methods for estimating glomerular filtration rate in patients with heart failure
by: Anna Jonsson, et al.
Published: (2020-06-01) -
Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01) -
Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01) -
Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts
by: Kunal Mahajan, et al.
Published: (2020-01-01) -
Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy
by: Neeraj Hiremath, et al.
Published: (2024-04-01)